Serious skin reactions from carbamazepine reports from thaivigibase
1 / 23

Serious skin reactions from Carbamazepine : reports from Thaivigibase - PowerPoint PPT Presentation

  • Uploaded on

Serious skin reactions from Carbamazepine : reports from Thaivigibase. Health Product Vigilance Center (HPVC) Food and Drug Administration, Ministry of Public Health, Thailand. Introduction.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Serious skin reactions from Carbamazepine : reports from Thaivigibase' - dick

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Serious skin reactions from carbamazepine reports from thaivigibase

Serious skin reactions from Carbamazepine : reports from Thaivigibase

Health Product Vigilance Center (HPVC)

Food and Drug Administration, Ministry of Public Health, Thailand

Introduction Thaivigibase

  • The most serious skin reactions reported from prescribing some group of drugs are Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

  • These reactions can lead patients severely ill and finally dead.

Introduction Thaivigibase

  • On December 2007, US. Food and Drug Administration (FDA) issued an alert for healthcare professionals concerning the dangerous or even fatal skin reactions (Stevens Johnson syndrome and toxic epidermal necrolysis), that can be caused by carbamazepine therapy.

Introduction Thaivigibase

  • The latest information about the genetic association of some drugs- serious reactions has been clarified.

  • The HLA- B*1502 allele (which caused SJS) is significantly more common in patients exclusively in patients with ancestry across broad areas of Asia, including South Asian Indians and Thais.

Introduction Thaivigibase

  • Descriptive analysis of adverse reactions from carbamazepine use in Thaivigibase would be compared those reactions to the new information in Thai patients.

  • Proper recommendation and regulatory action would be performed from this experience.

Review of carbamazepine
Review of Carbamazepine Thaivigibase

  • Carbamazepine is labeled for use in the following indication; Bipolar I disorder, acute manic and mixed episodes, Epilepsy, Partial, generalized, and mixed types , Glossopharyngeal neuralgia and Trigeminal neuralgia.

Side effects and toxicity
Side effects and toxicity Thaivigibase

  • Carbamazepine can produce dose-related adverse effects, which include dizziness, diplopia, nausea, ataxia, and blurred vision. Rare idiosyncratic adverse effects include aplastic anemia, agranulocytosis, thrombocytopenia, Stevens-Johnson syndrome and asymptomatic elevation of liver enzymes.

Objectives Thaivigibase

  • To describe and characterize skin and appendage adverse drug reaction reported in patients receiving carbamazepine in Thailand from Thaivigibase.

  • 5 years experience

Methodology Thaivigibase

  • During 2003 to 2007, we carried out a retrospective search in the Thaivigibase of spontaneous adverse drug reaction database.

  • Reports were included if they had been recorded at least one prescription of carbamazepine from the hospitals and clinics between January 1, 2003 to December 31, 2007.

Methodology Thaivigibase

  • A search of preferred term for potential cases were all reports of skin and appendage disorders.

  • Information on patient demographic information , medical history, clinical conditions and concomitant drug and sources of reports were collected.

Methodology Thaivigibase

  • Reports were excluded if they had no record of carbamazepine for suspected or concomitant drug during the study period.

  • Descriptive statistics was calculated. The analysis was performed with chart and cumulative percentage.

Results Thaivigibase

  • A total of 1,132 reports with 1,769 adverse reactions were reported during study period.

  • Most reports came from general hospitals (25.49%), center hospitals (25.04%) and community hospitals (19.80%).

Results Thaivigibase

  • The age range of reported cases was 3 months to 89 years (median, 44 years).

  • 693 reports of 1,132 reports (61.21%.) were male.

  • 19 of 154 reports (12.33%) with allergic history information had carbamazepine associated reaction experience.

Results Thaivigibase

  • 648 reports (57.24%) were serious adverse drug reactions. Almost of them (83.48%) resulted in admitted or prolonged hospitalization.

  • Two fatal outcome cases were reported due to Stevens-Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN).

Results Thaivigibase

  • 1,230 of 1,769 events (69.53%) were described as skin reaction

  • Stevens Johnson syndrome (SJS) was the most frequently reported event (32.85%)

  • followed by maculo-pupular rash ((13.50%) and rash (11.95%).

Results Thaivigibase

  • Other severe skin reaction including

    1.10.55% of erythema multiforme (EM)

    2.3.09% of toxic epidermal necrolysis (TEN)

Conclusions Thaivigibase

  • Stevens Johnson Syndrome (SJS) was the highest reported adverse drug reactions.

  • Our findings are consistent with available evidence with the literature reported.

Recommendations Thaivigibase

  • Further analytical study and pharmacogenomic study should be conducted.

  • HPVC center will collaborate with the genetic section to study the association and further reducing these severe skin reactions

Recommendations Thaivigibase

  • The cost-effectiveness study on gene testing before prescribing carbamazemine is ongoing performed.

Acknowledgements Thaivigibase

  • Networking centers contributing data to the Health Product Vigilance Center.

  • All staffs at Health Product Vigilance Center, FDA, Thailand.